Mosunetuzumab
Lunsumio (mosunetuzumab) is a prescription monoclonal antibody made by Genentech, Inc., used to treat certain types of follicular lymphoma in adults who have relapsed or not responded to other treatments. It's administered as an intravenous injection, available in concentrate forms like 1 mg/mL or 30 mg/30 mL vials. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Lunsumio (mosunetuzumab) is a prescription monoclonal antibody made by Genentech, Inc., used to treat certain types of follicular lymphoma in adults who have relapsed or not responded to other treatments. It's administered as an intravenous injection, available in concentrate forms like 1 mg/mL or 30 mg/30 mL vials. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Mosunetuzumab",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Mosunetuzumab — ANDA 761263 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761263"
}
]
|
| identifier | ANDA761263 |
| issued | 2016-09-16 |
| keyword |
[
"drug-safety",
"fda",
"health-care",
"pharmaceuticals",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Mosunetuzumab |
